ALPN - Alpine Immune Sciences Inc Stock Price, Fair Value and News

64.62USD+0.05 (+0.08%)Market Closed

Market Summary

USD64.62+0.05

Market Closed

0.08%

ALPN Stock Price

View Fullscreen

ALPN RSI Chart

ALPN Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

-131.61

Price/Sales (Trailing)

71.94

EV/EBITDA

-133.46

Price/Free Cashflow

-53.28

ALPN Price/Sales (Trailing)

ALPN Profitability

EBT Margin

-54.49%

Return on Equity

-9.81%

Return on Assets

-8.47%

Free Cashflow Yield

-1.88%

ALPN Fundamentals

ALPN Revenue

Revenue (TTM)

58.9M

Rev. Growth (Yr)

1.0K%

Rev. Growth (Qtr)

207.21%

ALPN Earnings

Earnings (TTM)

-32.2M

Earnings Growth (Yr)

131.59%

Earnings Growth (Qtr)

150.84%

Breaking Down ALPN Revenue

Last 7 days

0.3%

Last 30 days

72.6%

Last 90 days

157.3%

Trailing 12 Months

796.3%

How does ALPN drawdown profile look like?

ALPN Financial Health

Current Ratio

7.86

ALPN Investor Care

Shares Dilution (1Y)

37.25%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	25.8M	29.1M	30.8M	58.9M
2022	33.9M	32.0M	31.8M	30.1M
2021	11.4M	18.0M	24.6M	23.4M
2020	2.8M	3.0M	4.6M	9.3M
2019	0	1.1M	1.4M	1.7M
2018	1.5M	1.1M	910.2K	705.0K
2017	2.6M	2.3M	2.0M	1.7M
2016	0	0	1.7M	3.0M
2015	0	0	0	492.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alpine Immune Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	rickey james paul	acquired	977,844	8.30342	117,764	see remarks
Jan 26, 2024	rickey james paul	sold	-2,745,830	23.3164	-117,764	see remarks
Jan 25, 2024	rickey james paul	sold	-5,192	22.00	-236	see remarks
Jan 25, 2024	rickey james paul	acquired	1,536	6.51	236	see remarks
Jan 18, 2024	cui xiangmin	acquired	15,729,300	12.74	1,234,640	-
Jan 18, 2024	decheng capital china life sciences usd fund iii, l.p.	acquired	15,729,300	12.74	1,234,640	-
Jan 11, 2024	thompson peter a.	acquired	1,850,500	12.74	145,251	-
Jan 11, 2024	orbimed advisors llc	acquired	1,850,500	12.74	145,251	-
Jan 04, 2024	durand remy	acquired	-	-	31,200	chief business officer
Jan 04, 2024	gold mitchell	acquired	-	-	96,000	executive chairman and ceo

Which funds bought or sold ALPN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BFSG, LLC	reduced	-50.00	266	6,937	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-64.89	-19,000	51,000	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	new	-	3,032,780	3,032,780	-%
Apr 22, 2024	Vivo Capital, LLC	reduced	-36.47	5,178,790	20,794,200	1.63%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	127,985	320,551	-%
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	new	-	398,699	398,699	1.99%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	331	225,890	254,251	-%
Apr 10, 2024	Banque Cantonale Vaudoise	new	-	798,000	798,000	0.03%
Apr 05, 2024	GAMMA Investing LLC	added	59.26	987	1,705	-%
Mar 26, 2024	HighPoint Advisor Group LLC	new	-	570,000	570,000	0.04%

Are Funds Buying or Selling ALPN?

Are funds buying ALPN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALPN

No. of Funds

Unveiling Alpine Immune Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 07, 2024	blackrock inc.	4.6%	3,026,330	SC 13G/A
Feb 14, 2024	omega fund vi, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	paradigm biocapital advisors lp	5.5%	3,176,743	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	6.6%	3,813,926	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	4.39%	2,550,000	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	5,903,234	SC 13G/A
Feb 14, 2024	great point partners llc	6.37%	3,703,433	SC 13G/A
Feb 02, 2024	blackrock inc.	5.3%	3,058,498	SC 13G
Dec 29, 2023	orbimed advisors llc	4.6%	2,680,496	SC 13D/A
Nov 22, 2023	frazier life sciences viii, l.p.	4.7%	2,829,366	SC 13D/A

Recent SEC filings of Alpine Immune Sciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	SC 14D9	SC 14D9
Apr 22, 2024	SC TO-T	SC TO-T
Apr 11, 2024	SC TO-C	SC TO-C
Apr 10, 2024	8-K	Current Report
Apr 10, 2024	SC TO-C	SC TO-C
Apr 10, 2024	SC14D9C	SC14D9C
Apr 10, 2024	SC14D9C	SC14D9C
Apr 05, 2024	3	Insider Trading
Apr 05, 2024	8-K	Current Report
Mar 20, 2024	10-K	Annual Report

Peers (Alternatives to Alpine Immune Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Alpine Immune Sciences Inc News

Latest updates

Alpine Immune Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3
Revenue	207.2%	30,853,000	10,043,000	8,593,000	9,387,000	2,776,000	8,367,000	5,292,000	13,629,000	4,530,000	8,516,000	7,193,000	3,204,000	5,643,000	1,913,000	688,000	1,091,000	884,000	289,000	567,000	448,000	329,000
Operating Expenses	19.2%	29,306,000	24,593,000	24,248,000	24,979,000	23,145,000	22,199,000	21,781,000	21,086,000	19,906,000	21,779,000	17,924,000	13,693,000	12,104,000	8,884,000	10,440,000	6,656,000	7,901,000	11,999,000	12,719,000	11,445,000	12,386,000
S&GA Expenses	17.1%	6,374,000	5,443,000	5,007,000	5,398,000	4,389,000	4,610,000	4,194,000	4,775,000	4,544,000	3,470,000	3,290,000	3,256,000	3,049,000	2,728,000	3,344,000	1,778,000	2,102,000	2,467,000	2,553,000	2,514,000	1,857,000
R&D Expenses	19.7%	22,932,000	19,150,000	19,241,000	19,581,000	18,756,000	17,589,000	17,587,000	16,311,000	15,362,000	18,309,000	14,634,000	10,437,000	9,055,000	6,156,000	7,096,000	4,878,000	5,799,000	9,532,000	10,166,000	8,931,000	10,529,000
EBITDA Margin	70.5%	-0.53	-1.81	-1.96	-2.33	-1.81	-1.62	-1.61	-1.36	-2.09	-1.62	-1.81	-2.76	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	28,000	70,000	87,000	105,000	130,000	154,000	178,000	203,000	218,000	217,000	215,000	214,000	226,000	120,000	141,000	66,000	61,000	76,000	82,000
Income Taxes	-	103,000	-	-	-	548,000	-	1,778,000	4,000	-298,000	80,000	131,000	-	-	-	-6,000	-	-	-	-	-61,000	-
Earnings Before Taxes	151.7%	6,063,000	-11,722,000	-13,156,000	-13,266,000	-18,316,000	-13,273,000	-16,320,000	-7,523,000	-15,465,000	-13,414,000	-10,898,000	-10,643,000	-6,342,000	-6,137,000	-9,934,000	-	-6,140,000	-11,475,000	-11,856,000	-11,196,000	-12,139,000
EBT Margin	70.3%	-0.54	-1.83	-1.99	-2.37	-1.84	-1.65	-1.65	-1.40	-2.15	-1.68	-1.89	-2.89	-	-	-	-	-	-	-	-	-
Net Income	150.8%	5,960,000	-11,722,000	-13,156,000	-13,266,000	-18,864,000	-13,273,000	-18,098,000	-7,527,000	-15,167,000	-13,494,000	-11,029,000	-10,643,000	-6,342,000	-6,137,000	-9,928,000	-5,533,000	-6,140,000	-11,475,000	-11,856,000	-11,135,000	-12,139,000
Net Income Margin	70.5%	-0.55	-1.85	-2.01	-2.46	-1.92	-1.70	-1.70	-1.39	-2.15	-1.69	-1.90	-2.89	-	-	-	-	-	-	-	-	-
Free Cashflow	-20.8%	-19,085,000	-15,799,000	-18,370,000	-26,245,000	-16,902,000	-16,403,000	-16,284,000	5,423,000	-14,778,000	30,134,000	-14,712,000	-16,010,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	57.9%	380	241	253	262	287	292	216	234	256	233	160	130	144	154	103	50.00	54.00	65.00	70.00	67.00	55.00
Current Assets	67.2%	330	197	207	199	241	253	172	176	192	184	140	100	107	143	91.00	38.00	42.00	52.00	57.00	65.00	54.00
Cash Equivalents	131.4%	44.00	19.00	34.00	14.00	13.00	127	25.00	35.00	68.00	76.00	19.00	13.00	35.00	141	88.00	25.00	17.00	18.00	16.00	42.00	11.00
Net PPE	-3.2%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
Liabilities	-34.2%	52.00	79.00	83.00	93.00	107	110	116	119	135	111	116	77.00	82.00	87.00	86.00	25.00	25.00	30.00	25.00	11.00	10.00
Current Liabilities	-19.0%	42.00	52.00	53.00	57.00	58.00	68.00	63.00	68.00	70.00	64.00	60.00	43.00	41.00	36.00	28.00	5.00	9.00	14.00	13.00	9.00	8.00
Long Term Debt	-	-	-	-	-	-	-	1.00	2.00	3.00	5.00	6.00	6.00	8.00	9.00	10.00	8.00	5.00	5.00	1.00	2.00	2.00
LT Debt, Current	-	-	-	-	2.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	3.00	1.00	0.00	2.00	0.00	-	2.00	2.00	2.00
LT Debt, Non Current	-	-	-	-	-	-	-	1.00	2.00	3.00	5.00	6.00	6.00	8.00	9.00	10.00	8.00	5.00	5.00	1.00	2.00	2.00
Shareholder's Equity	102.9%	328	162	169	170	179	182	100	115	121	123	44.00	53.00	62.00	67.00	16.00	25.00	29.00	35.00	45.00	57.00	45.00
Retained Earnings	2.3%	-256	-262	-250	-237	-223	-205	-191	-173	-166	-151	-137	-126	-115	-109	-103	-93.46	-87.93	-81.79	-70.31	-58.45	-46.07
Additional Paid-In Capital	37.6%	584	424	420	407	404	389	293	290	287	274	181	180	178	177	120	118	117	117	116	115	91.00
Shares Outstanding	22.5%	60.00	49.00	49.00	48.00	46.00	32.00	30.00	30.00	25.00	25.00	24.00	24.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	349	-	-	-	132	-	-	-	105	-	-	-	50.00	-	-	-	21.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-20.1%	-18,971	-15,798	-18,091	-26,152	-16,786	-16,348	-16,069	5,449	-14,729	30,134	-14,682	-15,971	-9,349	-5,392	54,519	-9,694	-5,671	-10,575	-7,877	-11,223	-9,398
Share Based Compensation	5.6%	2,803	2,654	2,621	2,552	2,469	2,555	2,335	2,289	1,460	1,638	1,545	1,597	949	973	1,232	986	780	825	682	754	731
Cashflow From Investing	-20965.8%	-112,702	-535	29,328	28,350	-107,899	25,790	6,564	-37,803	-4,285	-62,515	20,866	-6,546	-96,849	1,843	9,057	13,130	4,388	10,863	-17,587	19,099	9,136
Cashflow From Financing	12940.0%	156,610	1,201	8,398	-1,087	11,543	92,816	-1,020	-650	10,873	89,680	9.00	202	-11.00	56,390	2.00	5,000	-	1,646	-509	23,118	-500

ALPN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration [Member]	Collaboration [Member]	Collaboration [Member]
Collaboration revenue	$ 58,876	$ 30,064	$ 23,443
Operating expenses:
Research and development	80,904	70,243	58,742
General and administrative	22,222	17,968	14,560
Total operating expenses	103,126	88,211	73,302
Loss from operations	(44,250)	(58,147)	(49,859)
Other income (expense):
Interest income	11,852	3,288	259
Interest expense	(98)	(476)	(816)
Other, net	415	(97)	(4)
Loss before taxes	(32,081)	(55,432)	(50,420)
Income tax (expense) benefit	(103)	(2,330)	87
Net loss	(32,184)	(57,762)	(50,333)
Comprehensive income (loss):
Unrealized gain (loss) on investments	1,493	(901)	(238)
Unrealized gain (loss) on foreign currency translation	25	53	(88)
Comprehensive loss	$ (30,666)	$ (58,610)	$ (50,659)
Weighted-average shares used to compute basic net loss per share (in shares)	50,000,339	33,435,280	25,476,889
Weighted-average shares used to compute diluted net loss per share (in shares)	50,000,339	33,435,280	25,476,889
Basic net loss per share (in dollars per share)	$ (0.64)	$ (1.73)	$ (1.98)
Diluted net loss per share (in dollars per share)	$ (0.64)	$ (1.73)	$ (1.98)

ALPN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 43,921	$ 13,376
Short-term investments	283,491	224,265
Accounts receivable	167	392
Prepaid expenses and other current assets	2,455	2,960
Total current assets	330,034	240,993
Restricted cash, noncurrent	268	254
Property and equipment, net	1,484	1,584
Operating lease, right-of-use asset	7,510	8,219
Long-term investments	40,556	35,481
Deferred tax asset	0	155
Total assets	379,852	286,686
Current liabilities:
Accounts payable	3,593	4,286
Accrued liabilities	21,187	14,003
Deferred revenue, current	16,288	35,571
Operating lease liability, current	912	756
Current portion of long-term debt	0	3,380
Total current liabilities	41,980	57,996
Deferred revenue, noncurrent	929	39,185
Operating lease liability, noncurrent	9,002	10,085
Total liabilities	51,911	107,266
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized at December 31, 2023 and 2022; zero shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2023 and 2022; 60,347,457 shares issued and outstanding at December 31, 2023; 47,234,900 shares issued and 45,984,433 shares outstanding at December 31, 2022	60	46
Treasury stock, at cost; zero and 1,250,467 shares at December 31, 2023 and 2022, respectively	0	0
Additional paid-in capital	583,629	404,456
Accumulated other comprehensive gain (loss)	397	(1,121)
Accumulated deficit	(256,145)	(223,961)
Total stockholders’ equity	327,941	179,420
Total liabilities and stockholders’ equity	$ 379,852	$ 286,686

About Alpine Immune Sciences Inc

Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

CEO	Dr. Mitchell H. Gold M.D.
WEBSITE	alpineimmunesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	126

Alpine Immune Sciences Inc Frequently Asked Questions

What is the ticker symbol for Alpine Immune Sciences Inc? What does ALPN stand for in stocks?

ALPN is the stock ticker symbol of Alpine Immune Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alpine Immune Sciences Inc (ALPN)?

As of Thu Apr 25 2024, market cap of Alpine Immune Sciences Inc is 4.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers. The fair value of Alpine Immune Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alpine Immune Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALPN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alpine Immune Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALPN is over valued or under valued. Whether Alpine Immune Sciences Inc is cheap or expensive depends on the assumptions which impact Alpine Immune Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALPN.

What is Alpine Immune Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, ALPN's PE ratio (Price to Earnings) is -131.61 and Price to Sales (PS) ratio is 71.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALPN PE ratio will change depending on the future growth rate expectations of investors.